Study guide
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines)
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines)
Key Takeaways Explain This Topic AI
First-trimester crown-rump length (CRL) ultrasound at 11–14 weeks is the clinical gold standard for gestational age assignment under SOGC guidelines, overriding LMP if dating differs by >5 days.
Cell-free fetal DNA / Non-Invasive Prenatal Testing (NIPT) provides >99% sensitivity for Trisomy 21 screening, but positive results require invasive diagnostic confirmation via CVS or amniocentesis.
Universal initial laboratory screening includes ABO/Rh blood typing, red cell antibody screen, CBC, rubella immunity, syphilis, HBsAg, HIV, and urine culture to detect asymptomatic bacteriuria.
Rh-negative unsensitized pregnant individuals must receive 300 mcg (1500 IU) Anti-D immune globulin (WinRho) IM at 28 weeks gestation and within 72 hours of delivering an Rh-positive infant.
Group B Streptococcus (GBS) rectovaginal screening is universally performed at 35–37 weeks gestation, with intrapartum IV Penicillin G indicated for positive cultures or risk-based criteria.
Last updated: July 2026
Routine Antepartum Care, Screening, & Prenatal Diagnosis
Routine antepartum care aims to optimize maternal and fetal outcomes through evidence-based screening, risk identification, and timely intervention. In Canadian obstetric practice, clinical management is strictly guided by the Society of Obstetricians and Gynaecologists of Canada (SOGC) clinical practice guidelines.
Gestational Age Determination & Prenatal Visit Schedule
Accurate gestational dating is essential for managing preterm labor, post-term pregnancy, growth restriction, and timing of screening tests.
Gestational Dating Rules
Naegele's Rule : Estimated Due Date (EDD) = First day of Last Menstrual Period (LMP) + 7 days - 3 months + 1 year. Assumes a regular 28-day cycle with ovulation on day 14.
Ultrasound Dating (SOGC Standard) : First-trimester crown-rump length (CRL) measured between 11+0 and 13+6 weeks is the gold standard for establishing gestational age (margin of error ±5 days).
Re-dating Criteria : If ultrasound CRL differs from LMP dating by >5 days in the first trimester (<9 weeks) or >7 days (9-14 weeks), the ultrasound EDD replaces the LMP EDD.
Routine Prenatal Visit Schedule
Gestational Age Visit Frequency Key Clinical Assessments
Initial Visit (8–12 weeks) Intake & baseline assessment Full history, physical exam, initial lab panel, baseline BP and weight, ultrasound for dating
Up to 28 weeks Every 4 weeks Blood pressure, fundal height (from 20 wks), fetal heart tones (FHT), maternal weight gain, fetal movement
28 to 36 weeks Every 2 weeks BP, fundal height, FHT, Rh status verification, 24–28 wk GDM screen, repeat antibody screen
36 weeks to delivery Every week BP, fundal height, FHT, fetal presentation/lie (Leopold maneuvers), GBS rectovaginal swab (35–37 wks)
Physical Examination Highlights
Fundal Height Measurement : Measured in centimeters from the pubic symphysis to the top of the uterine fundus. Between 20 and 36 weeks gestation, fundal height in centimeters correlates closely with gestational age in weeks (±2 cm).
Discordant Fundal Height (<2 cm expected) : Indicates intrauterine growth restriction (IUGR), oligohydramnios, fetal transverse lie, or incorrect dating. Mandates ultrasound for fetal biometry and amniotic fluid volume (AFI / DVP).
Discordant Fundal Height (>2 cm expected) : Indicates multifetal gestation, polyhydramnios, fetal macrosomia, uterine fibroids, or molar pregnancy.
Leopold Maneuvers : Four-step abdominal palpation technique performed in the third trimester to determine fetal lie (longitudinal, transverse, oblique), presentation (cephalic, breech), position, and engagement of the presenting part.
Initial Laboratory Screening Panel
At the first prenatal visit, a comprehensive blood and urine panel is performed universally across Canada:
ABO & Rh(D) Blood Type : Identifies maternal Rh negative status requiring alloimmunization prophylaxis.
Red Cell Antibody Screen (Indirect Coombs Test) : Detects maternal alloantibodies (e.g., Anti-D, Anti-K [Kell], Anti-E, Anti-c) capable of causing hemolytic disease of the fetus and newborn (HDFN). Anti-Kell antibodies are particularly treacherous because they cause both fetal hemolysis and erythroblast suppression in fetal bone marrow.
Complete Blood Count (CBC) : Baseline hemoglobin and hematocrit to screen for physiological or iron-deficiency anemia (defined by SOGC as Hb <110 g/L in 1st/3rd trimesters and <105 g/L in 2nd trimester).
Infectious Disease Serology :
Rubella IgG : Identifies non-immune women. Live attenuated MMR vaccine is strictly contraindicated during pregnancy ; non-immune mothers must receive MMR postpartum prior to discharge.
Varicella IgG : Assesses immunity against chickenpox. Susceptible mothers are offered post-exposure prophylaxis with Varicella Zoster Immune Globulin (VARIZIG) if exposed.
Syphilis Serology : Treponemal/non-treponemal testing (RPR/VDRL or EIA/CIA) to prevent congenital syphilis. Penicillin G is the only effective treatment in pregnancy (desensitization required if allergic).
Hepatitis B Surface Antigen (HBsAg) : Identifies maternal infection. Infants of HBsAg-positive mothers require Hepatitis B immune globulin (HBIG) and Hep B vaccine within 12 hours of birth.
HIV Screening : Universal opt-out screening. Combination antiretroviral therapy (ART) in pregnancy reduces vertical transmission risk to <1%.
Chlamydia & Gonorrhea : Nucleic acid amplification testing (NAAT) from urine or endocervical swab.
Urine Culture : Screens for asymptomatic bacteriuria (defined as ≥10^5 CFU/mL of a single organism). Must be treated with pregnancy-safe antibiotics (Nitrofurantoin, Amoxicillin-clavulanate, or Cefalexin) even if completely asymptomatic to prevent pyelonephritis, preterm labor, and low birth weight.
Prenatal Screening for Aneuploidy & Structural Abnormalities
Canadian guidelines advocate offering all pregnant individuals, regardless of maternal age, non-invasive screening for fetal aneuploidy (Trisomy 21 [Down syndrome], Trisomy 18 [Edwards syndrome], and Trisomy 13 [Patau syndrome]).
Non-Invasive Screening Modalities
Screening Test Gestational Window Components Trimester / Detection Rate (T21)
First Trimester Screening (FTS) 11+0 to 13+6 weeks Ultrasound Nuchal Translucency (NT) + serum PAPP-A + free β-hCG ~85–90% detection rate (5% false positive)
Second Trimester Serum Screen (Quad Screen) 15+0 to 20+6 weeks Serum AFP, total β-hCG, unconjugated estriol (uE3), Inhibin A ~75–80% detection rate (5% false positive)
Non-Invasive Prenatal Testing (NIPT / cfDNA) ≥10+0 weeks Cell-free fetal/placental DNA isolated from maternal plasma >99% detection for T21 (>98% T18/T13), false positive <0.1%
Clinical Pearl : NIPT is a screening test , not a definitive diagnostic test. A positive NIPT result MUST be confirmed via invasive diagnostic testing (CVS or amniocentesis) prior to making irreversible clinical decisions.
Invasive Diagnostic Testing
Chorionic Villus Sampling (CVS) : Performed at 11 to 14 weeks via transabdominal or transcervical route under ultrasound guidance. Samples placental chorionic villi. Allows earlier diagnosis; risk of procedure-related pregnancy loss is ~0.2–0.5%.
Amniocentesis : Performed at 15 to 20 weeks transabdominally. Samples amniotic fluid for fetal karyotype, chromosomal microarray, or PCR. Gold standard diagnostic tool; procedure-related loss risk is ~0.1–0.3%.
Rh Isoimmunization & Anti-D Prophylaxis (SOGC Guidelines)
Rh alloimmunization occurs when an Rh(D)-negative mother produces IgG antibodies against Rh(D)-positive fetal erythrocytes, leading to fetal hemolysis, anemia, hyperbilirubinemia, and hydrops fetalis (anasarca, pericardial/pleural effusion, ascites).
Prophylaxis Protocol for Unsensitized Rh-Negative Women
Routine 28-Week Administration : Give 300 mcg (1500 IU) Anti-D Immune Globulin (WinRho SD / RhoGAM) IM at 28 weeks gestation after confirming negative indirect Coombs antibody screen.
Postpartum Administration : Give 300 mcg Anti-D IM within 72 hours of delivery if the neonate is confirmed Rh(D)-positive or Rh-unknown.
Potentially Sensitizing Events : Administer Anti-D following any potential fetomaternal hemorrhage event at any point in pregnancy:
- Ectopic pregnancy, spontaneous/induced abortion, molar pregnancy
- Invasive procedures (CVS, amniocentesis, cordocentesis)
- Antepartum hemorrhage (placenta previa, placental abruption)
- Blunt abdominal trauma, external cephalic version (ECV)
Dosing Adjustments & Kleihauer-Betke Test : A standard 300 mcg dose neutralizes up to 15 mL of Rh-positive red blood cells (30 mL of whole fetal blood). Following major trauma or severe abruption, a Kleihauer-Betke (KB) stain or flow cytometry is performed to quantify fetomaternal hemorrhage and calculate additional required doses of Anti-D.
- Third-Trimester Screening & Monitoring
- Anatomical Ultrasound Survey
Performed routinely at 18 to 22 weeks gestation to assess structural fetal anatomy, fetal growth, amniotic fluid volume, placenta location (ruling out placenta previa), and cervical length.
Group B Streptococcus (GBS) Screening & Prophylaxis
Screening Window : Universal rectovaginal swab performed at 35 to 37 weeks gestation.
Indication for Intrapartum Antibiotic Prophylaxis (IAP) :
- Positive GBS rectovaginal swab at 35–37 weeks
- GBS bacteriuria at any time during current pregnancy
- Previous infant with invasive GBS disease
Unknown GBS status with risk factors: intrapartum fever (≥38.0°C), preterm labor (<37 weeks), or rupture of membranes ≥18 hours.
First-Line IAP Regimen : IV Penicillin G (5 million units IV loading dose, then 2.5–3.0 million units IV q4h until delivery) initiated at least 4 hours before birth.
Penicillin Allergy Regimen :
Low risk of anaphylaxis: IV Cefazolin 2 g loading, then 1 g q8h.
High risk of anaphylaxis: IV Clindamycin 900 mg q8h (if isolate is sensitive to clindamycin/erythromycin) OR IV Vancomycin 20 mg/kg q12h if resistant or sensitivity unknown.
SOGC Clinical Practice Pearls & Exam Traps
⚠️ EXAM TRAP : Live attenuated vaccines ( MMR, Varicella, Yellow Fever, LAIV flu ) are strictly contraindicated during pregnancy due to theoretical risks of fetal infection. However, inactivated Influenza vaccine (in any trimester) and Tdap vaccine (recommended during EVERY pregnancy between 27 and 32 weeks ) are actively indicated to confer passive neonatal immunity against pertussis.
🩺 CLINICAL SCENARIO : A 26-year-old G1P0 at 28 weeks gestation presents for routine care. Her blood type is A-negative and antibody screen is negative. What are the next immediate management steps?
Step 1 : Administer 300 mcg IM Anti-D immune globulin.
Step 2 : Perform routine 50g Glucose Challenge Test (GCT) for Gestational Diabetes screening.
Step 3 : Re-assess blood pressure and fundal height.